HR Execs on the Move


 
At Townsend’s Louisiana treatment centers, we care for addiction as a single disease that is typically self-treated with alcohol, drugs, gambling, sex, compulsive overeating, and other substances.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.townsendla.com
  • 4540 Ambassador Caffery Pkwy Ste c110
    Lafayette, LA USA 70508
  • Phone: 800.504.1714

Executives

Name Title Contact Details

Similar Companies

CinCor Pharma

CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases.

Engage Therapeutics

Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.

Jumpcode Genomics

JUMPCODE Genomic`s patented technology unlocks the power of Next Generation Sequencing by improving sensitivity, reducing costs, simplifying workflows and removing bias. Researchers around the world are using our CRISPRClean technology in the fields of infectious disease, oncology, consumer genomics, food science and basic research.

The Canadian Cancer Research Group

The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.